LARGE B-CELL LYMPHOMA (LBCL)
Clinical trials for LARGE B-CELL LYMPHOMA (LBCL) explained in plain language.
Never miss a new study
Get alerted when new LARGE B-CELL LYMPHOMA (LBCL) trials appear
Sign up with your email to follow new studies for LARGE B-CELL LYMPHOMA (LBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat lymphoma: triple-drug combo enters early trials
Disease control Not yet recruitingThis early-phase trial is testing whether a combination of three drugs (golcadomide, poseltinib, and rituximab) can shrink tumors in people with large B-cell lymphoma that has come back or not responded to prior treatment. The study will enroll 20 adults and measure how many pati…
Matched conditions: LARGE B-CELL LYMPHOMA (LBCL)
Phase: PHASE1, PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 17, 2026 04:54 UTC
-
Experimental CAR-T therapy targets tough lymphoma in tiny trial
Disease control Not yet recruitingThis early-stage study tests a new CAR-T cell therapy in 3 people with relapsed or treatment-resistant large B-cell lymphoma. The main goal is to check safety, looking for side effects like immune overreactions. Researchers will also see if the treatment shrinks tumors or leads t…
Matched conditions: LARGE B-CELL LYMPHOMA (LBCL)
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
AI takes on lymphoma: personalized treatment strategy under trial
Disease control Not yet recruitingThis study compares an AI-driven treatment strategy to standard therapy (Pola-R-CHP) for people with previously untreated large B-cell lymphoma. About 178 participants will be grouped by risk using an AI model, and those at intermediate or high risk will receive either a personal…
Matched conditions: LARGE B-CELL LYMPHOMA (LBCL)
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC
-
New hope: drug may prevent dangerous reactions to cancer immunotherapy
Disease control Not yet recruitingThis study tests whether the drug emapalumab can prevent severe side effects (cytokine release syndrome and nerve-related toxicity) in people with lymphoma or multiple myeloma receiving bispecific antibody therapy. About 60 adults will take emapalumab before their cancer treatmen…
Matched conditions: LARGE B-CELL LYMPHOMA (LBCL)
Phase: PHASE2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 02, 2026 11:57 UTC